Aflatoxin B 1 (AFB 1 ) is a potent human and animal hepatocarcinogen. To investigate the effects of aflatoxin on miRNA expression during the initiation phase of carcinogenesis, next-generation sequencing was used to analyze liver tissues from F344 rats exposed to 200 μg/kg per day AFB 1 for 4 week. A panel of miRNAs was identified that was upregulated with AFB 1 treatment compared to controls: rno-miR- 434-3p, rno-miR-411-5p, rno-miR-221-3p, rno-miR-127-3p, rno-miR-205, rno-miR-429, rno-miR-34a-5p, rno-miR-181c-3p, rno-miR-200b-3p, and rnomiR-541-5p. Analysis of rat livers exposed to AFB 1 plus the chemopreventive triterpenoid CDDO-Im revealed a striking abrogation of this upregulation. These changes were validated by real-time PCR. We also explored the temporal variation in expression of the candidate miRNAs during the 4-week dosing period. Most of the candidate miRNAs were upregulated at week 1 and increased for the duration of AFB 1 dosing over the 4-week period. Treatment with CDDOIm ameliorated these effects at all time points. All candidate miRNAs were detectable in serum from aflatoxin treated animals; however, there was no significant difference in expression for 7 of the 11 miRNAs examined. Exposure to AFB 1 upregulated miR-122-5p (fivefold), 34a-5p formal risk assessment that aflatoxin may singularly play a causal role in 4.6-28.2% of all HCC cases, with the population attributable risk estimated to be 17% in high exposure areas. 3,4 Thus, the public health impact of aflatoxin is substantial, spanning diverse populations, and warrants expanded effort in exposure mitigation and HCC prevention and early detection in these areas.
Im ameliorated these effects at all time points. All candidate miRNAs were detectable in serum from aflatoxin treated animals; however, there was no significant difference in expression for 7 of the 11 miRNAs examined. Exposure to AFB 1 upregulated miR-122-5p (fivefold), 34a-5p (13-fold), and 181c-3p (170-fold) compared with controls. The findings from this study give insight into epigenetic changes induced by aflatoxin taking place during the initial step of carcinogenesis.
K E Y W O R D S
aflatoxin B 1 , CDDO-Im, hepatocellular carcinoma, miRNA, RNA sequencing
| INTRODUCTION
Aflatoxin is a potent human and animal carcinogen produced by the fungi Aspergillus flavus and parasiticus that flourish on many staple food crops during environmentally stressful conditions. Ingestion of this compound leads to the development of hepatocellular carcinoma (HCC), the most common form of liver cancer. 1 HCC accounts for at least 750 000 deaths across the globe each year. 2 It is estimated by formal risk assessment that aflatoxin may singularly play a causal role in 4.6-28.2% of all HCC cases, with the population attributable risk estimated to be 17% in high exposure areas. 3, 4 Thus, the public health impact of aflatoxin is substantial, spanning diverse populations, and warrants expanded effort in exposure mitigation and HCC prevention and early detection in these areas. 5, 6 Mechanistic studies of aflatoxin have been accelerated through the development of a quantitative rat model that affords the opportunity to examine the biological impact of this carcinogen across the life course.
Many studies to date have shown that rats are highly susceptible to this toxin, develop preneoplastic foci and HCC, and utilize metabolic activation pathways yielding DNA adduct formation that are qualitatively and quantitatively very similar to humans. 6, 7 This quantitative rat model has also been used to evaluate a number of cancer chemoprotective agents, including the potent synthetic triterpenoid 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO-Im). 8, 9 In a recent bioassay,
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we observed that co-treatment of AFB 1 with CDDO-Im during a 28 day dosing period evoked complete protection against aflatoxin-induced hepatocarcinogenesis. 15, 16 There are very few studies that examine miRNA changes due to aflatoxin exposure, especially throughout the initiation and post-initiation phases of carcinogenesis.
In this study, we utilized next-generation sequencing to investigate the global miRNA profile of animals subchronically dosed with aflatoxin.
We also examined the impact of the chemopreventive agent CDDO-Im on miRNA expression. From these data, we have identified a panel of miRNAs that could be used to predict the trajectory to HCC following aflatoxin exposure.
| MATERIALS AND METHODS

| Biological sample selection
Tissue samples were obtained from a 4-week and a lifetime bioassay assessing burdens of DNA adducts and hepatic preneoplastic lesions that has been previously described. 9 Rats were randomly assigned to StepOne Plus System (Applied Biosystems). All assays were analyzed in triplicate. The relative amount of each miRNA was calculated using the 2 −ΔΔCt method. 18 
| Statistical analysis
Graphs represent the mean ± SD. All statistical analyses were performed using GraphPad Prism 7.0 software. Analysis of variance (ANOVA) tests were used for statistical analysis of differences among the three treatment groups followed by Tukey's multiple comparisons test. The level of significance was set at P < 0.05; *P < 0.05; **P < 0.005; ***P < 0.0005. Initial experiments were performed to quantitatively characterize the global miRNA expression profiles in rat liver using RNA sequencing.
| Clinical chemistry measurements
Samples were obtained from both animals that had been fed a control diet and rats that had been dosed for 28 consecutive days with AFB 1 , a cancer-inducing regimen. The AFB 1 exposed animals had been further divided into two experimental groups; one of which received additionally the chemoprotective triterpenoid CDDO-Im during the dosing protocol ( Fig. 1 ). All of these rat liver samples had been obtained as part of a liver cancer study that demonstrated the nearly complete protection (96%) against aflatoxin-induced hepatocarcinogenesis by CDDO-Im. 9 Thus, this study explored the patterns of miRNAs during the critical initiation phase of aflatoxin-induced carcinogenesis that establishes the trajectory to disease outcome over the lifetime of the rat.
A total of nine liver samples from the 4-week protocol; three control diet, three AFB 1 , and three AFB 1 plus CDDO- 
| Validation of sequencing data by RT-qPCR
To independently validate the small RNA sequencing data set described above, candidate miRNAs were examined in detail by RTqPCR. Qualitatively, the results from the RT-qPCR analyses proved to be completely consistent with the RNA sequencing data. This prompted a more detailed set of quantitative studies using RTqPCR. The criteria for selecting candidate miRNAs included biological significance in the literature and a focus on miRNAs that displayed greater than a 10-fold change in hepatic expression between control and AFB 1 treatment groups, as these might exhibit sufficient dynamic range as to make them suitable as biomarkers. The miRNAs rno-miR-541-5p, 34a-5p, 127-3p, 205, 434-3p, 429, 411-5p, 181c-3p, 200b-3p, 221-3p were selected because RNA-seq data showed that they were all upregulated in the AFB 1 -treated samples compared to controls (Table 2 ). These miRNAs are either identical to human miRNAs or have human homologs. In addition, the putative liver specific rno-miR-122 was also examined. Prior studies have shown this miRNA to be the most abundant in the liver amounting to 52% of the total miRNAs in the human liver. 19, 20 Figure 3 depicts the miRNA findings from the RT-qPCR experiments. ANOVA statistical tests revealed that all of the candidate miRNAs were significantly upregulated in AFB 1 treated samples, with rno-miR-541 having the largest increase compared to control (∼1000 fold). Treatment with CDDO-Im reduced the expression levels of all candidate miRNAs; even shifting expression levels for rno-miR-411-5p and rno-miR-127-3p to below control levels (Fig. 3) . Analysis of clinical chemistries in serum samples at the 4-week dosing point was also performed in parallel to miR-122 expression levels. Studies have shown miR-122 as an indication of liver toxicity and its potential use as a biomarker of acute liver injury in humans. [21] [22] [23] [24] [25] Results from this study revealed no increase in serum ALT and AST levels, suggesting a compensating mechanism occurring in the livers of these animals despite being given 28 doses of AFB 1 (Table S2) . For AST, all animals had levels below 210 U/L except for one animal. All animals had ALT levels below 80 U/L.
| Temporal trends in miRNA expression during chronic dosing of AFB 1 and its modulation by CDDOIm
Most studies in the current literature evaluating miRNA expression during disease focus on one specific time point, particularly at end stage disease diagnosis. To further understand the effect of AFB 1 on 127-3p, 541-5p). rno-miR-34a showed a marked increase after just seven doses of AFB 1 and maintained increased expression throughout the dosing period (Fig. 4A) . The miRNAs 181c-3p and 541-5p displayed the most dramatic change in expression between the first and last week of treatment. Co-treatment with CDDO-Im attenuated these effects with expression levels of all candidate miRNAs not exhibiting statistically significant changes over the dosing period (Fig. 4B,D) . Thus, the selected candidate miRNAs were all upregulated and tracked with aflatoxin dosing over time. This effect was reversed by chemoprotective intervention with CDDO-Im, further highlighting the possible role of these miRNAs as candidate biomarkers of risk of developing HCC.
| Detection of candidate miRNAs in serum samples
It is known from the literature that miRNAs are highly stable in the circulation, found in extracellular vesicles or bound to proteins. 26, 27 To examine the potential of the candidate miRNAs identified in this study to be reliable blood-based biomarkers, the miRNAs described above were explored in serum by RT-qPCR at the end of the 4-week dosing period.
These experiments showed that all candidate miRNAs were detectable in aflatoxin treated samples; however, there was no significant difference in expression for 7 of the 11 miRNAs examined (Fig. 5 ). Exposure to AFB 1 significantly upregulated miR-122-5p (fivefold), 34a-5p (13 fold), and 181c-3p (170 fold) compared with controls. Interestingly for miR-541, treatment with AFB 1 dramatically decreased the expression of this miRNA, though not statistically significant. Co-treatment with CDDO-Im eliminated these changes. Serum samples from animals diagnosed with HCC (only exposed to aflatoxin) were also examined and compared to sera obtained from animals at the same age dosed with CDDO-Im or controls. According to preliminary data, the miRNAs 34a-5p and 181c-3p were detectable in all serum samples, but miRs-122-5p and 541 were not detectable in the control samples. The expression levels of these four miRNAs were found to be identical in the aflatoxin and aflatoxin plus CDDO-Im treatment groups.
Further studies tracking patterns of serum miRNA across time-course after the dosing regimen and leading to cancer will need to be done to validate any of the other candidate miRNAs as biomarkers of HCC.
| DISCUSSION
MicroRNAs play an important role in biological processes such as embryogenesis, cell growth and differentiation, and tumorigenesis.
The altered expression of miRNAs due to disease or environmental exposures has been shown in multiple organisms, but little research has been done during cancer initiation with environmental carcinogens such AFB 1 . Some miRNAs have been identified as potential disease biomarkers for liver cancer based on miRNA targets and functionality, such as miR-122-5p and miR-429. [28] [29] [30] In such studies, however, the focus is on end stage disease. [31] [32] [33] [34] [35] Few studies have examined how aflatoxin affects miRNA expression. [36] [37] [38] [39] [40] The present study used a quantitative rat model to explore the dysregulation of miRNAs during cancer initiating exposure to aflatoxin but before the development of clinical disease. Global miRNA profiles were agnostically obtained using next-generation RNA sequencing that identified a subset of miRNAs for validation.
In this study, rats dosed with aflatoxin over four consecutive weeks had 96 differentially expressed hepatic miRNAs compared to controls, with the majority being upregulated. From that expression abundance data, further analysis yielded a candidate list of 10 miRNAs, which were all significantly upregulated compared to controls. Real-time PCR analysis of candidate miRNAs in liver tissue after 4 weeks of dosing (mean ± SD). Fold change calculated using the 2 −ΔΔCt method. (*) indicates significant difference (P < 0.05) when compared to control for that miR, (**) indicates significant difference (P < 0.01) when compared to control for that miR, (***) indicates significant difference (P < 0.001) when compared to control for that miR hepatic expression of miRNAs such as miR-34a and 92a. 39 A study by This miRNA is typically downregulated in HCC, but studies have found miR-34a to be increased in response to genotoxic agent exposure. 42, 43 In this investigation miR-34a could be upregulated at such an early time point in response to aflatoxin exposure (Fig. 4A ). Also Real-time PCR analysis of candidate miRNAs in serum after 4 weeks of dosing (mean ± SD). Fold change calculated using the 2 −ΔΔCt method. Large variability in rno-miR-541 expression in aflatoxin group due to an animal outlier. (*) indicates significant difference (P < 0.05) when compared to control for that miR, (**) indicates significant difference (P < 0.01) when compared to control for that miR, (***) indicates significant difference (P < 0.001) when compared to control for that miR dysregulated in many cancers, miR-429 (a member of the miR-200 family) has been shown to be involved in metastasis in HCC and correlated with higher burden of aflatoxin-DNA adducts. 30, 44 The mir181c-3p was one of many surprising candidate miRNAs found in this study. This miRNA is thought to be protective in leukemia and glioblastoma. 45, 46 Little information is known about this miR in the context of HCC except a study showing subsequent increase in expression after Wnt/β-catenin signaling activation. 47 We also found several miRNAs to be exclusively induced by aflatoxin ( Table 1) . Many of those were chosen as candidate miRNAs in a separate analysis.
Additional standouts from this exclusive list include rno-miR-204-5p
and rno-miR-410-3p. Important for eye development and adipogenesis, miR-204 is reported to be a tumor suppressor in HCC. 48, 49 miR-410 is clustered with miR-541, a candidate miRNA we identified in this study, and is shown to be overexpressed in clinical liver cancers. 50 This miRNA has also been found to be upregulated in human liver cells after exposure to aflatoxin. 38 The majority of microRNAs are stable molecules with a subset that are very dynamic with turnover rates ranging from hours to days. 51 To see how the hepatic expression of the candidate miRNAs change over the course of the 4 week dosing period, we analyzed their expression by RT-qPCR after 7, 14, 21, and 28 doses of AFB1. Most of the candidate miRNAs increased in expression and tracked with aflatoxin exposure over the dosing period, except rno-miR-122-5p and rno-miR-34a-5p which had constant high expression. miR-122 is the most abundant miRNA in the liver, so its high expression is expected. Additionally, the human miR-122 gene has been shown to contain the binding site for hepatocyte nuclear factor 4 alpha (HNF4α), a transcription factor involved in liver development, which can upregulate miR-122 expression in human Huh7 and HepaRG cells. 38, 52, 53 Therefore, the dysregulation of rno-miR-122 in this study could also be explained by the modulation of HNF4α by aflatoxin. Recent evidence has
shown that miR-34a is transcriptionally regulated by p53 and involved in liver regeneration. 36, 54 We hypothesize that the high constant expression of miR-34a during the dosing period could be due to the role of this miR in these processes. Rno-miR-541-5p had the largest significant change in expression between the first and last weeks of dosing. Little is known about this miR in the literature. In cancer, studies have found the human analogue of rno-miR-541 to be a tumor suppressor by regulating telomerase expression and targeting TGIF2 in non-small cell lung cancer. 55, 56 Another microRNA found to be significantly increased during the dosing period was rno-miR-200b-3p. Related to rno-miR-429, the expression of this miRNA has been found to be reduced in methyl-deficient diet-induced HCC in rats and in HepG2 cells. 57, 58 A study by has also found the human analogue of miR-200b to be downregulated in tumor tissue directly targeting DNA methyltransferase 3a (DNMT3a) expression. 57 Co-treatment with CDDO-Im resulted in no significant change in the hepatic expression of any of the candidate miRNAs over the 4-week dosing period.
Circulating miRNAs are very attractive as a minimally invasive biomarker: they are detectable in serum and plasma, resistant to RNase activity, and stable at different temperatures and pHs. 59, 60 We examined the plausibility of the candidate miRNAs, which were highly dysregulated in liver tissue, to be reliable blood-based biomarkers that predict the trajectory to developing HCC. Analysis of serum samples revealed significantly increased circulating levels of rno-miRs 122-5p, 34a-5p, and 181c-3p in animals after 28 doses of aflatoxin. Co-treatment CDDO-Im attenuated this effect, as seen in other experiments throughout this study. We also wanted to see if the miRs 34a, 181c-3p, and 541 were dysregulated in the sera of animals during end-stage disease since they were the most dysregulated miRNAs in tissue and serum during the initiation phase of the disease.
Preliminary data revealed that these miRNAs were not useful at these late time points, most likely due to the complex tumor biology taking place. They may be more advantageous in indicating early biological changes occurring in the cancer initiation phase during and following exposure to aflatoxin.
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